Oruka Therapeutics (NASDAQ:ORKA) Now Covered by Wolfe Research

Wolfe Research started coverage on shares of Oruka Therapeutics (NASDAQ:ORKA) in a research report sent to investors on Tuesday, Marketbeat reports. The brokerage issued an outperform rating and a $20.00 price objective on the stock.

Other research analysts have also recently issued research reports about the company. Stifel Nicolaus assumed coverage on Oruka Therapeutics in a research report on Friday, October 11th. They set a “buy” rating and a $49.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $45.00 price objective on shares of Oruka Therapeutics in a report on Friday, December 20th. Finally, Wedbush reiterated an “outperform” rating and issued a $40.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, November 19th. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $39.86.

Oruka Therapeutics Stock Performance

Oruka Therapeutics stock opened at $14.21 on Tuesday. Oruka Therapeutics has a twelve month low of $10.95 and a twelve month high of $53.88. The company has a market cap of $497.35 million, a PE ratio of -2.27 and a beta of 0.77. The firm has a 50-day moving average of $18.09.

Hedge Funds Weigh In On Oruka Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of ORKA. AlphaCentric Advisors LLC bought a new position in Oruka Therapeutics in the 4th quarter valued at approximately $119,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Oruka Therapeutics during the 4th quarter valued at $144,000. Geode Capital Management LLC acquired a new position in Oruka Therapeutics in the 3rd quarter worth about $343,000. The Manufacturers Life Insurance Company bought a new position in Oruka Therapeutics in the third quarter valued at about $1,037,000. Finally, Wellington Management Group LLP acquired a new position in shares of Oruka Therapeutics in the third quarter valued at approximately $2,013,000. Institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.